Core Insights - Novo Nordisk's Wegovy tablets exceeded 18,000 prescriptions in the first full week post-launch in the U.S., indicating a strong market entry for the oral weight loss drug [1] - Analysts noted that the prescription data suggests a high early adoption rate, outpacing other GLP-1 drugs in the market [1] - The shift towards cash payment models by pharmaceutical companies is contributing to the positive reception of Wegovy [1]